|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||125.09 - 125.82|
|52 Week Range||104.94 - 126.68|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
In 2Q17, United Therapeutics (UTHR) generated revenues of around $445 million, which reflected ~8% growth on a year-over-year (or YoY) basis and ~20% growth on a quarter-over-quarter basis.
Should investors consider fundamentally weighted strategies?
In 2016, United Therapeutics’ (UTHR) Remodulin reported revenues of ~$602.3 million, which reflected ~5.0% year-over-year growth.